These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29957060)

  • 21. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
    Huang Y; Yu H; Lei H; Xie C; Zhong Y
    Med Oncol; 2014 Mar; 31(3):824. PubMed ID: 24469951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
    Pardini B; Rosa F; Naccarati A; Vymetalkova V; Ye Y; Wu X; di Gaetano C; Buchler T; Novotny J; Matullo G; Vodicka P
    Carcinogenesis; 2015 Jan; 36(1):82-6. PubMed ID: 25368035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
    Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Atsushi Nanashima ; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
    Cancer Lett; 2004 Feb; 204(1):97-104. PubMed ID: 14744539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
    Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
    Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
    Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
    Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
    EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy.
    Wang Z; Jiang B; Chen L; Di J; Cui M; Liu M; Ma Y; Yang H; Xing J; Zhang C; Yao Z; Zhang N; Dong B; Ji J; Su X
    J Transl Med; 2014 Jan; 12():15. PubMed ID: 24444035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
    Lin LW; Lai PS; Chen YY; Chen CY
    Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 35. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postoperative adjuvant chemotherapy with 1-hexylcarbamoyl-5-fluorouracil in patients with colorectal cancer and at a high risk for recurrence.
    Maehara Y; Sugimachi K; Ogawa M; Kakegawa T; Tomita M; Akiyoshi T
    Anticancer Res; 1998; 18(6B):4629-34. PubMed ID: 9891531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
    Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
    BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
    Zawiah M; Yousef AM; Kadi T; Yousef M; Majdalawi K; Al-Yacoub S; Al-Hiary R; Tantawi D; Mukred R; Ajaj AR
    Drug Metab Pers Ther; 2018 Dec; 33(4):201-205. PubMed ID: 30207288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection.
    Chien H; Chu YD; Hsu YP; Yeh CT; Lai MW; Chang ML; Lim SN; Chen CW; Lin WR
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.